KRAS and Miyoshi myopathy: Some of the common variants underwent selection and outgrowth (35/141, 25%) (e.g., KRAS c.182A>T (patient 10), c.35G>C (patient 7), c.176C>A (patient 26), BRCA2 c.8182G>A (patient 28), KMT2C c.1014G>A (patient 27), TET2 c.1841G>A (patient 21), CYLD c.1240C>T (patient 31), TP53 c.796G>T (patient 26)), some declined (41/141, 29%), but most (65/141, 46%), tended to be stable during MM progression (Figure 3).